Long term follow-up of Behcet's syndrome patients treated with cyclophosphamide

Abstract

Objectives. CYC remains an important treatment option for Behcet's syndrome (BS) patients with life-threatening manifestations. However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides. We investigated short and long term adverse events associated with CYC use in BS patients.